IV ST-001 nanoFenretinide produced a 28% response rate in heavily pretreated cutaneous T-cell lymphoma in a first-in-human phase 1a trial.
Commentary|Videos|December 10, 2024
Dr Lee on Real-World Early Outcomes With Second-Line Axi-Cel for R/R LBCL
Author(s)Dasom (Caroline) Lee, MD
Dasom (Caroline) Lee, MD, discusses real-world early outcomes of treatment with second-line axi-cel in relapsed/refractory large B-cell lymphoma.
Advertisement
Dasom (Caroline) Lee, MD, Hematology and Medical Oncology Fellowship Program, Stanford Medicine, Stanford Health Care, discusses real-world early outcomes of treatment with second-line axicabtagene ciloleucel (axi-cel; Yescarta) in relapsed/refractory large B-cell lymphoma. Lee and colleagues shared these results in a presentation at the
Advertisement
Related to this article
Real-world treatment with pegylated interferon alfa-2a tolerable, and treatment-related AEs were manageable in patients with cutaneous T-cell lymphoma.
Translational profiling tied CCR4 loss, IL enrichment, and BCL-2 upregulation to mogamulizumab resistance; venetoclax may be a combination partner.
Real-world mogamulizumab reduced skin symptoms and improved health-related quality of life in patients with mycosis fungoides and Sézary syndrome.
Dibotatug was deemed tolerable and produced robust responses across subgroups of patients with relapsed/refractory cytotoxic T/NK cell lymphomas.
BI-1808 as a single agent and in combination with pembrolizumab elicited responses and was generally well tolerated in patients with CTCL.
The final analysis of the Italian FIL-MOGA study showed an objective response lasting at least 4 months in 47% of patients and identified the measure as a surrogate for survival outcomes.
In an MAIC, mogamulizumab led to an OS improvement vs vorinostat in patients with relapsed/refractory mycosis fungoides or Sézary syndrome.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
Five Under 5: Top Oncology Videos for the Week of 6/28
3
The OncFive: Top Oncology Articles for the Week of 6/28
4
Divesiran Reduces Phlebotomy Burden and Improves Iron Stores in Polycythemia Vera
5